Showing results (871-880 of 1,107) with videos related to

Sort By:
Pageof 111
European Urology|September 17, 2013
Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortalityAndrew J Stephenson, Scott E Eggener, Adrian V Hernandez, et al.
Physical Review Letters|April 4, 2020
High-Rate, High-Fidelity Entanglement of Qubits Across an Elementary Quantum NetworkL J Stephenson, D P Nadlinger, B C Nichol, et al.
Plos One|September 17, 2015
A Sweetpotato Geranylgeranyl Pyrophosphate Synthase Gene, IbGGPS, Increases Carotenoid Content and Enhances Osmotic Stress Tolerance in Arabidopsis thalianaWei Chen, Shaozhen He, Degao Liu, et al.
The Journal of Urology|September 25, 2017
Genomic Scores are Independent of Disease Volume in Men with Favorable Risk Prostate Cancer: Implications for Choosing Men for Active SurveillanceYaw A Nyame, Dominic C Grimberg, Daniel J Greene, et al.
Clinical Colorectal Cancer|February 11, 2009
An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumorsJoe J Stephenson, Charles Gregory, Howard Burris, et al.
Sleep|November 25, 2010
Reliability and validity of the brief insomnia questionnaire in the America insomnia surveyRonald C Kessler, Catherine Coulouvrat, Goeran Hajak, et al.
Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie|February 12, 2026
Gene therapy outcomes in young patients with RPE65-retinal degenerationKirk A J Stephenson, Abrar K Alsalamah, Anupreet Tumber, et al.
Annals of the New York Academy of Sciences|June 18, 1999
Virtual biopsies in Barrett's esophagus using an impedance probeC A González-Correa, B H Brown, R H Smallwood, et al.
Medical & Biological Engineering & Computing|September 14, 2000
Assessing the conditions for in vivo electrical virtual biopsies in Barrett's oesophagusC A González-Correa, B H Brown, R H Smallwood, et al.
Investigational New Drugs|August 25, 2011
A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapyRamesh K Ramanathan, Joe J Stephenson, Glen J Weiss, et al.
Pageof 111